Zydus Cadila Healthcare Limited

What Zydus Cadila Healthcare Limited does

Zydus Cadila Healthcare Limited, operating as Zydus Lifesciences Limited, is a publicly listed Indian pharmaceutical company (NSE: ZYDUSLIFE, BSE: 532321) headquartered in Ahmedabad, Gujarat, and ranked 4th in the Indian pharmaceutical industry. Founded in 1952, the group employs over 29,000 people globally and operates more than 30 manufacturing plants across India (Gujarat, Maharashtra, Goa, Himachal Pradesh, Sikkim), Brazil, and the United States. Its commercial footprint spans regulated markets (US, Europe — France and Spain), high-profile emerging markets (Latin America, South Africa), and 25+ other emerging markets worldwide. The business is structured around six revenue streams: pharmaceutical formulations and generics, Active Pharmaceutical Ingredients (APIs), biosimilars and biologics, vaccines, animal health and wellness products, and licensing/out-licensing.

The company's product portfolio is differentiated by multiple first-in-class and world-first innovations: Lipaglyn (Saroglitazar) — India's first NCE to reach market, indicated for diabetic dyslipidemia; Twinrab — the world's first novel rabies monoclonal antibody cocktail (Docaravimab and Miromavimab) for post-exposure prophylaxis; Exemptia — the world's first biosimilar of Adalimumab for autoimmune disorders; Vaxiflu-4 — India's first tetravalent inactivated influenza vaccine; and BEIZRAY, a 505(B)(2) oncology product licensed from Beihai Biotech for the US market. The innovation engine is built around 1,500 researchers across 19 R&D sites working across NCEs, biosimilar therapeutic proteins, biosimilar monoclonal antibodies, biobetters, novel biologics, and vaccines spanning cardio-metabolic, inflammation/immunology, neurosciences, oncology, and rare diseases. Sub-brands include Zydus Biologics (biosimilars portfolio) and Zydus Therapeutics, alongside the India Formulations and Generics divisions. The company also operates a 25-year-old joint venture with Takeda (Zydus Takeda Healthcare) for manufacturing operations in India.

Zydus monetizes through a hybrid B2B go-to-market: direct enterprise sales for India domestic formulations and international generics, channel partners/distributors across emerging markets, dedicated biosimilars commercialization, and licensing royalties (e.g., BEIZRAY). Pricing is not publicly disclosed and is determined by market, regulatory jurisdiction, and contracting arrangements. Financial performance disclosed for Q3 FY25 was revenue from operations of Rs. 52,691 mn (up 17% YoY) and net profit of Rs. 10,235 mn (up 30% YoY), with Mr. Pankaj R. Patel serving as Chairman.

Name

Zydus Cadila Healthcare Limited

Legal name

Zydus Cadila Healthcare Limited

Website

https://zyduscadila.com

Company type

Public

Founded year

1952

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Zydus Cadila Healthcare Limited (Zydus Lifesciences) is a publicly listed Indian pharmaceutical company, ranking 4th in India with 29,000+ employees and 30+ manufacturing plants. It develops NCEs, biosimilars, vaccines, and complex generics for regulated markets (US, Europe) and 25+ emerging markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Manufacturing, Private Label & Co-Manufacturing for Animal Diets (HLAMAHAO)

Keywords

• Pharmaceutical formulations
• Generic medicines
• Biosimilar therapeutics
• Vaccines manufacturing
• Active pharmaceutical ingredients

Headquarters

HQ city

Ahmedabad, Gujarat

HQ country

India

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical formulations and generics: Sale of finished pharmaceutical formulations across India and international markets including regulated markets (US, Europe) and emerging markets. Revenue from both brand-name and generic drug sales across multiple therapeutic areas.
2. Active Pharmaceutical Ingredients (APIs): Manufacturing and sale of APIs to third-party pharmaceutical companies for use in their formulations.
3. Biosimilars and biologics: Commercialization of biosimilar therapeutic proteins, biosimilar monoclonal antibodies, biobetters and novel biologics across multiple markets.
4. Vaccines: Development and commercialization of vaccines including the tetravalent inactivated influenza vaccine Vaxiflu-4 and vaccine pipeline candidates.
5. Animal health and wellness products: Diversified product portfolio covering animal health products and wellness consumer products.
6. Licensing and out-licensing: Revenue from licensing, supply and commercialization agreements for proprietary products in international markets such as the BEIZRAY agreement with Beihai Biotech for the US market.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Zydus Cadila Healthcare Limited (operating as Zydus Lifesciences Limited) manufactures and commercializes a diversified pharmaceutical portfolio including branded formulations (TwinrabTM, Lipaglyn, Exemptia, Vaxiflu-4), generic formulations, biosimilars, vaccines, Active Pharmaceutical Ingredients (APIs), complex products (transdermals, topicals), animal health and wellness products. The company serves regulated markets (US, Europe — France and Spain), Latin America, South Africa and 25 other emerging markets from more than 30 manufacturing plants worldwide.

Product overview

Zydus Lifesciences is a diversified pharmaceutical company with a portfolio spanning innovative medicines, generics, biosimilars, and vaccines. The company's product portfolio includes branded products such as TwinrabTM (rabies monoclonal antibodies), Lipaglyn (diabetic dyslipidemia treatment), Exemptia (biosimilar Adalimumab), and Vaxiflu-4 (influenza vaccine). The company operates through sub-brands including Zydus Biologics (biosimilars portfolio) and Zydus Therapeutics, alongside India Formulations and Generics divisions. Manufacturing capabilities cover formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical), animal health products, and wellness products across more than 30 manufacturing plants worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• TwinrabTM World's First Novel Rabies Monoclonal Antibodies (mAbs) cocktail containing Docaravimab and Miromavimab, providing dual protection against rabies for post-exposure prophylaxis (PEP).
• Lipaglyn (Saroglitazar) Novel drug to treat diabetic dyslipidemia, addressing a global unmet healthcare need. First New Chemical Entity (NCE) from an Indian research pipeline to move from the lab to the market.
• Exemptia (Adalimumab biosimilar) World's first biosimilar of Adalimumab, the largest selling therapy globally for treating autoimmune disorders. Provides treatment for inflammatory arthritis and access for Indian patients who did not previously have access to this therapy.
• Vaxiflu-4 India's first Tetravalent Inactivated Influenza vaccine providing protection from four influenza viruses: H1N1, H3N2, Type B (Brisbane) and Type B (Phuket).
• BEIZRAY (Albumin Solubilized Docetaxel Injection) Albumin Solubilized Docetaxel Injection, a 505(B)(2) oncology product for the US market, exclusively licensed by Zydus from Beihai Biotech for commercialization and supply in the United States.
• Zydus Biologics portfolio (biosimilars and novel biologics) Portfolio of biosimilar therapeutic proteins, biosimilar monoclonal antibodies, biobetters, and novel biologics developed by Zydus across multiple therapeutic areas.
• India Formulations (domestic branded generics) Pharmaceutical formulations marketed in India across multiple therapeutic areas including diabetes, autoimmune disorders and infectious diseases, distributed through pharmaceutical distribution networks across India.
• International Generics Business Generic pharmaceutical products for global markets including regulated markets of the US and Europe (France, Spain), and high-profile markets of Latin America and South Africa.
• Active Pharmaceutical Ingredients (APIs) Active Pharmaceutical Ingredients manufactured and sold to third-party pharmaceutical companies for use in their own formulations.
• Animal health and wellness products Diversified portfolio of animal health products and wellness consumer products manufactured by the Zydus group.

Quantifiable outcome

• Q3 FY25 Revenue from operations at Rs. 52,691 mn, up 17% YoY; Net Profit at Rs. 10,235 mn, up 30% YoY

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Beihai BiotechcoreTechnology or Integration · 14 February 2025Zydus and Beihai Biotech signed an exclusive licensing, supply and commercialization agreement for BEIZRAY (Albumin Solubilized Docetaxel Injection), a 505(B)(2) product for the US market. This agreement grants Zydus exclusive rights to commercialize the product in the United States.
• TakedacoreStrategic or Co-development Partner · 30 January 2025Zydus Takeda Healthcare, the joint venture entity, marked 25 years of manufacturing operations in India. This partnership represents a long-standing strategic manufacturing collaboration between Zydus and Takeda in India.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Lupin Limited: Indian pharma major with significant US generics presence, complex generics (inhalables, injectables), and biosimilar ambitions. Directly competes in US regulated-market generics and Indian domestic formulations.
• Torrent Pharmaceuticals: Indian pharma with strong domestic branded presence and a growing international generics and branded business across regulated and emerging markets, including Brazil. Comparable in therapeutic areas like cardio-metabolic and CNS.
• Glenmark Pharmaceuticals: Indian pharma company with focus on branded generics, specialty/innovator R&D, and emerging market presence. Overlaps with Zydus in India formulations, branded specialty products, and select emerging market geographies.
• Aurobindo Pharma: Top-5 Indian generic manufacturer with a large US and European generics footprint, broad API capabilities, and growing biosimilar and injectable businesses. Comparable on scale of US business and manufacturing footprint.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company with a similar diversified portfolio spanning formulations, generics, APIs, and specialty/innovator products across US, India, and emerging markets. Direct competitor in Indian generics, US generics, and branded specialty franchises.
• Cipla Limited: Top Indian pharmaceutical company operating across formulations, APIs, and complex generics with strong presence in India, US, South Africa, and emerging markets. Overlaps directly with Zydus in respiratory, anti-infectives, and chronic disease therapies.
• Dr. Reddy's Laboratories: Major Indian pharma with overlapping presence in US generics, biosimilars, APIs, and emerging markets. Comparable in terms of regulated-market focus, biosimilars ambition (including rituximab and bevacizumab), and complex injectable portfolio.
• Biocon Limited: India's leading biosimilars and biologics player with global commercialization partnerships and a strong R&D platform. Directly comparable on biosimilars (Adalimumab, Trastuzumab, Insulin Glargine) and biologics manufacturing scale.

Broad incumbents

• Viatris Inc. Global generics and biosimilars powerhouse formed from Mylan-Upjohn combination, with deep US/EU generics portfolio and established biosimilar franchises. Direct overlap with Zydus on US generics revenue and biosimilar competition.
• Novartis AG (Sandoz): Global pharma major with Sandoz division as a leading biosimilars and generics player. Comparable on biosimilars (Hyrimoz/Adalimumab competes with Exemptia), vaccines pipeline reach, and global commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ZydusUniverse
• YouTubeyoutube.com/channel/UCI_plFGyaPT631UONG4ajUQ
• Facebookfacebook.com/zydusuniverse
• LinkedInlinkedin.com/company/zydus-cadila-healthcare-limited
• Instagraminstagram.com/zydusuniverse

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zydus Cadila Healthcare Limited